Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Factors affecting outcome in the treatment of Glioblastoma (CROSBI ID 320135)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Koruga, Nenad ; Pekmezović, Tatjana ; Tomaš, Ilijan ; Soldo Koruga, Anamarija ; Butković Soldo, Silva ; Užarević, Zvonimir ; Rotim, Krešimir Factors affecting outcome in the treatment of Glioblastoma // Acta clinica Croatica, 60 (2021), 3; 373-378. doi: 10.20471/acc.2021.60.03.06

Podaci o odgovornosti

Koruga, Nenad ; Pekmezović, Tatjana ; Tomaš, Ilijan ; Soldo Koruga, Anamarija ; Butković Soldo, Silva ; Užarević, Zvonimir ; Rotim, Krešimir

engleski

Factors affecting outcome in the treatment of Glioblastoma

Treatment of glioblastoma is challenging due to its aggressive and highly invasive nature, and no significant advances in survival have been achieved recently. The aim of our retrospective study was identification of predictive factors and consequent survival outcome in patients who underwent surgical and oncologic treatment of glioblastoma. The study was conducted at the Department of Neurosurgery, Osijek University Hospital Centre. The authors designed a retrospective cohort study in 63 patients who underwent surgical and oncologic treatment between January 1, 2012 and December 31, 2017. Data were collected by reviewing medical records of the patients with histologically proven glioblastoma. Statistical analysis of study results revealed a significant impact of postoperative radiotherapy (p=0.002) and chemotherapy (p=0.016) on progression-free survival and overall survival (p=0.001 and p=0.009, respectively). Postoperative Karnofsky performance scale (p=0.027) was found to be significant in progression-free survival, and so was the interval between surgery and commencement of oncologic therapy (p=0.049). In conclusion, overall survival and prognosis in the treatment of glioblastoma remain poor, although prompt approach in postoperative adjuvant treatments improved progression-free survival.

Brain neoplasms ; Glioblastoma ; Radiotherapy ; Temozolomide ; Procarbazine

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

60 (3)

2021.

373-378

objavljeno

0353-9466

1333-9451

10.20471/acc.2021.60.03.06

Povezanost rada

Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

Poveznice
Indeksiranost